AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Innate Pharma S.A. ADS
XNAS · usd
SIC 8731 · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
FIGI BBG009ZCBWH4
1.50▲ 0.00 (0.00%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
1.50
Day's Range
1.48 – 1.52
52-Week Range
1.18 – 2.71
Volume
11.6K
Avg Volume
49.2K
Share Statistics
Shares Outstanding
Employees
163
Exchange
XNAS
Listed
2015-09-09
Share count as of December 31, 2025

Innate Pharma S.A. ADS (IPHA) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Innate Pharma S.A. ADS (IPHA)
What is Innate Pharma S.A. ADS's Market Cap?
Innate Pharma S.A. ADS's Market Cap is $140.6M, based on as-reported figures from SEC (XBRL) filings.
What is Innate Pharma S.A. ADS's Enterprise Value?
Innate Pharma S.A. ADS's Enterprise Value is $133.2M, based on as-reported figures from SEC (XBRL) filings.
What is Innate Pharma S.A. ADS's Price / Sales?
Innate Pharma S.A. ADS's Price / Sales is 12.4×, based on as-reported figures from SEC (XBRL) filings.
What is Innate Pharma S.A. ADS's EV / Revenue?
Innate Pharma S.A. ADS's EV / Revenue is 11.8×, based on as-reported figures from SEC (XBRL) filings.
What is Innate Pharma S.A. ADS's EV / EBITDA?
Innate Pharma S.A. ADS's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Innate Pharma S.A. ADS's Revenue (TTM)?
Innate Pharma S.A. ADS's Revenue (TTM) is $11.3M, based on as-reported figures from SEC (XBRL) filings.
What is Innate Pharma S.A. ADS's Net Income (TTM)?
Innate Pharma S.A. ADS's Net Income (TTM) is -$55.0M, based on as-reported figures from SEC (XBRL) filings.
What is Innate Pharma S.A. ADS's EBITDA?
Innate Pharma S.A. ADS's EBITDA is -$53.7M, based on as-reported figures from SEC (XBRL) filings.
What is Innate Pharma S.A. ADS's Diluted EPS (TTM)?
Innate Pharma S.A. ADS's Diluted EPS (TTM) is -0.59, based on as-reported figures from SEC (XBRL) filings.
What is Innate Pharma S.A. ADS's EBITDA Margin?
Innate Pharma S.A. ADS's EBITDA Margin is -474.4%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · IPHAAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of EUR, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017
Profit (loss) [abstract]
Revenue from collaboration and licensing agreements
Government financing for research expenditures
Other income
Revenue and other income
Research and development expenses
General and administrative expenses
Operating expenses
Operating income (loss)
Financial income
Financial expenses
Net financial income (loss)
Net income (loss) before tax
Net income (loss)